HelloBetter, a European leader in digital therapeutics for mental health and a global pioneer in digital mental health research, is excited to announce that it has successfully raised €6,000,000 in its latest funding round. Since its founding in 2015, HelloBetter has consistently pushed the boundaries of digital healthcare, developing a robust evidence base with a total of 33 randomized controlled trials published in highly respected, peer-reviewed journals. Today, the company stands at the forefront of transforming mental health treatment, as demonstrated by its six available therapy programmes in Germany that have become a part of the standard of care, benefiting over 70 million people who access treatment as prescription digital therapeutics (DiGA).
This significant funding injection will play a pivotal role in furthering HelloBetter’s mission to expand access to quality mental health care and bolster its research into innovative digital solutions. With a clear commitment to evidence-based approaches, the new capital will be allocated towards enhancing existing therapy programmes, accelerating breakthrough research, and broadening market reach, including the strategic move into the US. In 2022, the company successfully introduced its HelloGina brand to the US market, offering a sexual wellness program designed to support individuals with vaginismus. Furthermore, the groundbreaking achievement in 2023 of receiving Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic stands as a testament to the company’s dedication to pushing forward the edge of digital mental health innovation.
Ultimately, the raised funds represent an investment not only in HelloBetter’s promising future but also in a broader vision of enabling more people to access effective, high-quality mental health care through pioneering digital solutions.
